Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Neumora Therapeutics (Nasdaq: NMRA) reported positive preclinical results for NMRA-215, an oral, brain-penetrant NLRP3 inhibitor for obesity. In three diet-induced obesity mouse studies, NMRA-215 produced up to 19% weight loss as a monotherapy and up to 26% weight loss in combination with semaglutide. The company plans to initiate a Phase 1 clinical study in Q1 2026. Additional data will be presented during a virtual R&D day on October 27, 2025 with a webcast and 30-day replay.
Neumora Therapeutics (Nasdaq: NMRA) ha riportato risultati preclinici positivi per NMRA-215, un inibitore NLRP3 orale in grado di attraversare la barriera emato-encefalica per l'obesità. In tre studi su topi con obesità indotta da dieta, NMRA-215 ha prodotto fino a una perdita di peso del 19% come monoterapia e fino a una perdita di peso del 26% in combinazione con semaglutide. L'azienda prevede di avviare uno studio clinico di fase 1 nel primo trimestre del 2026. Ulteriori dati verranno presentati durante una giornata virtuale di R&D il 27 ottobre 2025 con una webcast e replay di 30 giorni.
Neumora Therapeutics (Nasdaq: NMRA) reportó resultados preclínicos positivos para NMRA-215, un inhibidor oral de NLRP3 capaz de atravesar la barrera hematoencefálica para la obesidad. En tres estudios en ratones con obesidad inducida por dieta, NMRA-215 obtuvo hasta un 19% de pérdida de peso como monoterapia y hasta un 26% en combinación con semaglutida. La empresa planea iniciar un ensayo clínico de Fase 1 en el primer trimestre de 2026. Se presentarán datos adicionales durante un día virtual de I+D el 27 de octubre de 2025 con transmisión y repetición de 30 días.
네우모라 테라퓨틱스(Nasdaq: NMRA)가 NMRA-215에 대한 긍정적인 전임상 결과를 발표했다. 구강 경구로 뇌에 침투하는 NLRP3 억제제이며 비만 치료제를 목표로 한다. 식이 유도 비만 마우스 실험 3건에서 NMRA-215는 단독 요법으로 최대 19% 체중 감소, 그리고 세마글루타이드와의 병용으로 최대 26% 체중 감소를 나타냈다. 회사는 2026년 1분기에 1상 임상시험을 시작할 계획이다. 추가 데이터는 2025년 10월 27일의 가상 R&D 데이에 발표될 것이며, 생중계와 30일 재방송이 제공된다.
Neumora Therapeutics (Nasdaq: NMRA) a annoncé des résultats précliniques positifs pour NMRA-215, un inhibiteur oral de NLRP3 capable de traverser la barrière hémato‑encéphalique, pour l'obésité. Dans trois études sur des souris obèses induites par un régime alimentaire, NMRA-215 a produit jusqu'à une perte de poids de 19% en monothérapie et jusqu'à 26% en association avec la sémaglutide. L'entreprise prévoit de lancer une étude clinique de phase 1 au premier trimestre 2026. Des données supplémentaires seront présentées lors d'une journée virtuelle R&D le 27 octobre 2025 avec diffusion en direct et révision sur 30 jours.
Neumora Therapeutics (Nasdaq: NMRA) berichtete positive präklinische Ergebnisse für NMRA-215, einen oralen, gehirnpassierenden NLRP3-Hemmer zur Fettleibigkeit. In drei Diät-induzierte Fettleibigkeits-Mausstudien führte NMRA-215 als Monotherapie zu bis zu 19% Gewichtsverlust und in Kombination mit Semaglutid zu bis zu 26% Gewichtsverlust. Das Unternehmen plant, eine Phase-1-Studie im ersten Quartal 2026 zu beginnen. Weitere Daten werden während eines virtuellen R&D-Tages am 27. Oktober 2025 mit Webcast und 30-tägiger Wiedergabe präsentiert.
Neumora Therapeutics (Nasdaq: NMRA) كشفت عن نتائج ما قبل السريرية الإيجابية لـ NMRA-215، وهو مثبط NLRP3 عن طريق الفم ويمكنه اختراق الدماغ لعلاج السمنة. في ثلاث دراسات على فئران مصابة بالسمنة الناتجة عن النظام الغذائي، أظهر NMRA-215 انخفاضًا في الوزن يصل إلى 19٪ كوحدة علاجية أحادية و حتى 26٪ عند استخدامه مع سيماغلوتيد. تخطط الشركة لبدء دراسة سريرية من المرحلة الأولى في الربع الأول من 2026. وسيتم عرض بيانات إضافية خلال يوم افتراضي للبحث والتطوير في 27 أكتوبر 2025 مع بث حي وإعادة عرض لمدة 30 يومًا.
Neumora Therapeutics（纳斯达克股票代码 NMRA） 公布了 NMRA-215 的积极前临床结果，这是一种口服、能穿透大脑的 NLRP3 抑制剂，用于治疗肥胖。在三项以饮食诱导的肥胖小鼠研究中，NMRA-215 作为单药治疗可实现多达 19% 的体重减轻，且与西马鲁肽联合使用时可实现多达 26% 的减重。公司计划在 2026 年第 1 季 启动一项临床 I 期研究。其他数据将于 2025 年 10 月 27 日 的虚拟研发日上发布，提供网络直播和 30 天回放。
- Monotherapy weight loss up to 19% in DIO mice
- Combination weight loss up to 26% with semaglutide
- Phase 1 start planned in Q1 2026
- Results are limited to preclinical DIO mouse studies; human safety and efficacy are unknown
Insights
Preclinical mouse data show strong weight‑loss signals for NMRA-215; clinical proof will hinge on Phase 1 human translation.
Neumora reports that oral NMRA-215 produced up to
Translation risk is the primary dependency. Mouse DIO models often overstate human efficacy and safety, so human pharmacokinetics, brain exposure, tolerability, and target engagement must be demonstrated before clinical relevance is established. The announced intent to start a Phase 1 study in
Key items to watch: initiation and completion of the Phase 1 study, human PK and brain-penetration evidence, safety/tolerability signals, and any early pharmacodynamic or weight-related biomarkers reported during the study.
NMRA-215 demonstrated class-leading weight loss of up to
NMRA-215 demonstrated best-in-class weight loss of up to
Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215
Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026
WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. NMRA-215 demonstrated class-leading weight loss of up to
“We are very encouraged by the results of the DIO studies with NMRA-215, which validate its potential as a class-leading, novel, brain-penetrant, oral NLRP3 inhibitor for obesity,” said Paul Berns, co-founder, chief executive officer and chairman, Neumora. “These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens. These data reinforce our conviction that NMRA-215 may be an effective, next-generation, oral treatment for obesity, both as a monotherapy as well as in combination with a GLP-1 agonist. We are looking forward to moving this program into the clinic in the first quarter of 2026.”
Neumora will present additional data during its virtual R&D day on October 27, 2025 at 8:00am ET.
Webcast Information
Neumora will host a virtual R&D day at 8:00 a.m. ET on Monday, October 27, 2025. Participants can register for the live webcast here. In addition, the live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About NMRA-215
NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity. The NLRP3 inflammasome is a critical part of the innate immune system that responds to pathogens and cellular damage and is implicated in both CNS and peripheral system disorders. NLRP3-mediated neuroinflammation in the hypothalamus is lined to obesity, and targeting NLRP3 in the hypothalamus is hypothesized to modulate dysfunctional neuronal circuitry related to appetite, leading to decreased food intake. Neumora is also exploring the potential of a NMRA-215 inhibitor program for the treatment of Parkinson’s disease.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; the timing, progress and plans for its therapeutic development programs, including the NMRA-215 studies, best-in-class pharmacology and the potential of NLRP3 inhibitors in obesity; the potential for Neumora to continue to advance NMRA-215; the potential benefits of NMRA-215; intellectual property protection and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including contract research organizations; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 which was filed with the SEC on August 6, 2025. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
FAQ
What weight loss did NMRA-215 achieve in the October 27, 2025 preclinical announcement for NMRA?
When does Neumora plan to start the Phase 1 study for NMRA-215 (NMRA)?
How was NMRA-215 administered in the reported studies for NMRA on October 27, 2025?
Does the October 27, 2025 release show human trial results for NMRA-215 (NMRA)?
Will Neumora present more NMRA-215 data and where can investors watch?
